Get the Stockscreener App
3.43
13.58%
0.41
Indaptus Therapeutics Inc stock is traded at $3.43, with a volume of 234.45K.
It is up +13.58% in the last 24 hours and up +55.20% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$3.02
Open:
$3.012
24h Volume:
234.45K
Relative Volume:
0.40
Market Cap:
$6.01M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-1.8641
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
+9.58%
1M Performance:
+55.20%
6M Performance:
-71.05%
1Y Performance:
+308.28%
1-Day Range:
$3.01
$3.66
1-Week Range:
$2.986
$3.66
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
3.43 | 5.29M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
MACD Signal: Is Indaptus Therapeutics Inc stock a good pick for beginnersEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Will Indaptus Therapeutics Inc. stock recover faster than marketFit and Size Notes & lightweight options for faster days - ulpravda.ru
Indaptus Therapeutics appoints David Natan to board and audit committee By Investing.com - Investing.com Nigeria
Indaptus Therapeutics appoints David Natan to board and audit committee - Investing.com
Indaptus Therapeutics Appoints David Natan to Board - TipRanks
Will Indaptus Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда
How analysts rate Indaptus Therapeutics Inc. stock todayEarnings Risk Report & Weekly Hot Stock Watchlists - Улправда
Why did INDP stock gain 12% today? - MSN
Indaptus Therapeutics announces upcoming board leadership transition - MSN
Three Indaptus Therapeutics board members signal planned resignations By Investing.com - Investing.com Nigeria
Three Indaptus Therapeutics board members signal planned resignations - Investing.com
Indaptus Therapeutics Announces Board Resignations - TradingView — Track All Markets
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 25.9% in December - Defense World
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Biotech Stocks To Keep An Eye OnDecember 24th - MarketBeat
Indaptus Therapeutics Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - marketscreener.com
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar - The Globe and Mail
Indaptus Therapeutics secures $6 million investment, names new chairman By Investing.com - Investing.com Nigeria
Why Did INDP Stock Gain 12% Today? - Stocktwits
Indaptus Therapeutics stock falls after $6 million securities deal By Investing.com - Investing.com Nigeria
Indaptus Therapeutics stock falls after $6 million securities deal - Investing.com
Penny Stocks Worth Watching – December 25th - Defense World
What Does the Market Think About Indaptus Therapeutics Inc? - Benzinga
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Indaptus Therapeutics Inc.: Are They Ready for Takeoff? - StocksToTrade
Indaptus Therapeutics, Inc.Common Stock (Nasdaq:INDP) Stock Quote - FinancialContent
Is It Too Late to Buy INDP Stock? - timothysykes.com
Indaptus Therapeutics (INDP) Stock in Focus on Dec. 24, 2025: $6M Financing, Leadership Reset, and the Dilution Question - ts2.tech
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Indaptus Therapeutics, Uipath, Trinity Biotech, Sable Offshore And McDonald's: Why These 5 Stocks Are On Investors' Radars Today - Sahm
Indaptus Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Trending Stocks Today | Indaptus Therapeutics Soars 52.9% Post-Market - 富途牛牛
Indaptus Therapeutics Inc appoints David Lazar as co-chief executive officer - marketscreener.com
Indaptus Therapeutics Signs Securities Purchase Agreement With David Lazar - TradingView — Track All Markets
INDP Files 8-K with SEC - Stock Titan
Indaptus Therapeutics, Inc. announced that it has received $6 million in funding - marketscreener.com
Indaptus Therapeutics, Inc. announced that it expects to receive $6 million in funding - marketscreener.com
Can Indaptus Therapeutics Inc. stock hit record highs again2025 Top Gainers & Precise Entry and Exit Recommendations - Улправда
How buybacks impact Indaptus Therapeutics Inc. stock valueTrade Analysis Summary & AI Forecast for Swing Trade Picks - Улправда
Breakout Move: Is Indaptus Therapeutics Inc stock attractive for hedge fundsJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - moha.gov.vn
Will Indaptus Therapeutics Inc. stock outperform value stocksShort Setup & Weekly High Potential Stock Alerts - DonanımHaber
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):